Skip to main navigation
X
Announcing our new website:
KindredBio Equine
  • Sign In
KindredBio
  • About
    • Background
    • KindredBio Leadership
    • Board Of Directors
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Products
    • Mirataz™ (mirtazapine transdermal ointment)
  • Pipeline
    • Pipeline
    • Zimeta™ (dipyrone)
    • epoCat™ (feline recombinant erythropoietin)
  • Investors

    Investor Relations

    • Investor Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Stock Information
      • Stock Quote
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • Proxy Online
    • Investor Resources
      • Information Request
      • E-mail Alerts
      • IR Contact
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Search

Press Releases

You are here:Home/Investors/ Press Releases

Press Releases

Keyword Search

Kindred Biosciences Announces Half-Life Extension Technology for Canine Antibodies

January 8, 2020

- Positive results from canine pharmacokinetic study demonstrate up to three-fold...

Investor Relations

  • Investor Overview
  • Press Releases
  • Events and Presentations
  • Corporate Governance
    • Governance Documents
    • Committee Composition
  • Stock Information
    • Stock Quote
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Proxy Online
  • Investor Resources
    • Information Request
    • E-mail Alerts
    • IR Contact

INVESTOR TOOLS

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contact

News

  • Kindred Biosciences Announces Half-Life Extension Technology for Canine AntibodiesJanuary 8, 2020 4:02 PM EST
  • Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in DogsDecember 16, 2019 8:02 AM EST
  • Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight LossDecember 12, 2019 9:05 AM EST

Events

  • Half-Life Extension Technology for Canine Antibodies
    Wednesday, January 8, 2020 4:30 PM EST
  • Kindred Biosciences Inc at the Jefferies London Healthcare Conference
    Thursday, November 21, 2019
  • Kindred Biosciences, Inc.at the Stifel 2019 Healthcare Conference
    Tuesday, November 19, 2019 from 10:20 AM to 10:50 AM EST
 
(Common Stock)
Previous Close Volume
Intraday High Intraday Low
52 Week High 52 Week Low
Exchange:

KindredBio proudly supports
Rabies Free Africa
Rabies free Africa

© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010 | Privacy Policy| Website Terms of Use| Forward Looking Statements
Scroll to top